510(k) Premarket Submission — TissueLink Medical, Inc. — Bipolar Floating Ball device
KaLQ2o0s TY MAY 2 0 2002
——__
510(k) Summary of Safety and Effectiveness
This summary of 510(k)-safety and effectiveness information is being submitted in accordance with the
requirements of SMDA 1990 and 21 CFR 807.92.
Application Information:
Date Prepared: February 19, 2002
Submitter: TissueLink Medical Inc.
Address: One Washington Center Suite 400
Dover, NH 03820
Contacts: Vicki S. Anastasi
Directory Regulatory Affairs
Telephone Number: (508) 922-1622
: FAX Number: (508) 497-9925
Roberta L. Thompson
Vice President, Clinical, Regulatory and Quality
Telephone Number: (603) 742-1515 ext. 106
Fax Number: (603) 742-1488
Device Information:
Trade Name: TissueLink Bipolar Floating Ball device
Common Name: Electrosurgery Cauterizing Pen
Classification Name: Electrosurgical cutting and coagulation device and accessories, 21CFR
878.4400
Predicate Devices:
Claim of Substantial Equivalence of the TissueLink Bipolar Floating Ball device is made to:
TissueLink Monopolar Floating Ball
TissueLink Medical, Inc. 15

grag , cS = mS a
f & DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
: % . i / "Nn : | : : oe Food and Drug Administration —
: - 9200 Corporate Boulevard
: : MAY 3 0 2002 Rockville MD 20850
. Ms. Vicki S. Anastasi / me .
‘ Director, Regulatory Affairs Se oe
TissueLink Medical, Inc. . :
, One Washington Center, Suite 400 a
: Dover, NH 03820
Re: K020574
Trade/Device Name: TissueLink Bipolar Floating Ball Device
Regulation Number: 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories.
Regulatory Class: I
Product Code: GEI
Dated: February 19, 2002
Received: February 21, 2002
Dear Ms. Anastasi:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing 21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

: _ Page 2—Ms. Vicki S. Anastasi —- . /
. This letter will allow you.to begin marketing -your device as described in your Section 510(k)
. - premarket notification. The FDA finding of substantial equivalence of your device toalegally >. .
marketed predicate device results in a classification for your device and thus, permits your device
’. to proceed to the market. , . . a
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and
additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of
Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of
your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the
regulation entitled, "Misbranding by reference to premarket notification” (21CFR Part 807.97).
Other general information on your responsibilities under the Act may be obtained from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 443-6597 or at its Internet address
http://www. fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
/himeann C. frevo.T
£0" Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure

, . 510(k) Premarket Submission - TissueLink Medical, Inc. — Bipolar Floating Ball device a .
SL Lo __. Indiéations for use Statement . : —_
. / . , . / Page of ..
: oo 510(k) Number (if known): Ko a O48" 4- .
Device Name: _.. TissueLink Bipolar Floating Ball device :
Indications for Use:
The TissueLink Bipolar Floating Ball device is a sterile, single use bipolar electrosurgery device
intended to be used in conjunction with an electrosurgical generator for delivery of
radiofrequency current and saline for-hemostatie-sealing and coagulation of soft-tissue at the
operative site. It is intended for, but not limited to, endoscopic and open abdominal, general and
thoracic surgery. The device is not intended for contraceptive tubal coagulation (permanent
female sterilization).
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V OR Over-The-Counter Use
(Per 21 CFR 801.109) . Optional Format 1Vuicam C. Prevod

(Division Sign-Off)

Division of General, Restorative

and Neurological Devices

__K62 0674

TissueLink Medical, Inc. 510(k) Number 14

